Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1999-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/j.1365-2125.1999.00903.xPMID 10215754PMCID PMC2014217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Roche, FDA announce new drug-interaction warnings for mibefradil.

  1998cited by this paper
• Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

  1998cited by this paper
• Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man.

  1997cited by this paper
• In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.

  1997cited by this paper
• Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.

  1997cited by this paper
• Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men

  1997cited by this paper
• Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

  1996cited by this paper
• In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

  1996cited by this paper
• Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents

  1996cited by this paper
• Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.

  1995cited by this paper
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995cited by this paper
• Macrolides Versus Azalides: A Drug Interaction Update

  1995cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine

  1994cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole

  1994cited by this paper
• Biotransformation of fluvastatin sodium in humans.

  1993cited by this paper
• IV. Identification of Cytochrome P450 3A Proteins as the Major Enzymes Responsible for the Oxidative Metabolism of Lovastatin in Rat and Human Liver Microsomes

  1991cited by this paper
• Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

  1991cited by this paper
• Ro 40–5967: A New Nondihydropyridine Calcium Antagonist

  1991cited by this paper
• Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents.

  1990cited by this paper

• The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4

  2025influential citation
• Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy

  2024influential citation
• 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.

  2023cites this paper
• Non-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes.

  2022cites this paper
• Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.

  2022cites this paper
• Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation.

  2022cites this paper
• Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore

  2021influential citation
• Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4

  2021cites this paper
• Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes

  2021influential citation
• Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6′,7′-Dihydroxybergamottin

  2019cites this paper
• Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?

  2019cites this paper
• Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

  2019cites this paper
• Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans.

  2019cites this paper
• Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib

  2017influential citation
• ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules

  2015cites this paper
• Pharmacological Profiles of T-Type Calcium Channel Antagonists

  2015cites this paper
• Drug–Drug Interaction: From Bench to Drug Label

  2015cites this paper
• Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes

  2015cites this paper
• Physiologically-based pharmacokinetic modelling and simulation of oral drug bioavailability: Focus on bariatric surgery patients and mechanism-based inhibition of gut wall metabolism

  2014cites this paper
• Investigation of Drug Interaction Studies of Levocetirizne with HMG-CoA Reductase Inhibitors

  2014cites this paper
• Identification and mechanistic investigation of clinically important myopathic drug-drug interactions

  2014cites this paper
• Role of genetic polymorphisms of drug metabolising enzymes in idiosyncratic drug reactions In vitro to in vivo translation

  2013cites this paper
• Drug interactions with statins

  2013cites this paper
• Assessing the Hepatic Disposition and Toxicity of Xenobiotics Using Primary Hepatocytes

  2012cites this paper
• 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets.

  2012cites this paper
• Sequential Metabolism of AMG 487, a Novel CXCR3 Antagonist, Results in Formation of Quinone Reactive Metabolites That Covalently Modify CYP3A4 Cys239 and Cause Time-Dependent Inhibition of the Enzyme

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012cites this paper
• ADME of Biologics—What Have We Learned from Small Molecules?

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012cites this paper
• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  2012cites this paper
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cites this paper
• Mechanism-Based Inactivation of Cytochrome P450 3A4 by Mibefradil through Heme Destruction

  2011influential citation
• Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment.

  2011cites this paper
• Running title : CYP 3 A 4 Heme Destruction by Mibefradil *

  2011influential citation
• An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

  2011cites this paper
• An evaluation of the dilution method for identifying metabolism-dependent inhibitors (MDIs) of cytochrome P450 (CYP) enzymes

  2011cites this paper
• A Refined Cytochrome P450 IC50 Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors

  2011cites this paper
• Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships

  2011influential citation
• Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions

  2010cites this paper
• CYP Inhibition-Mediated Drug-Drug Interactions

  2010cites this paper
• PALACKÝ UNIVERSITY OLOMOUC

  2010cites this paper
• Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes

  2010cites this paper
• Clinical importance of the drug interaction between statins and CYP3A4 inhibitors

  2010cites this paper
• Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors

  2009cites this paper
• Application of mechanism-based CYP inhibition for predicting drug–drug interactions

  2009cites this paper
• Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development

  2009cites this paper
• Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?

  2009cites this paper
• Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.

  2008cites this paper
• In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats

  2008cites this paper
• Mechanism-Based Inactivation of Cytochrome P450 2A and 2B Enzymes

  2008cites this paper
• The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil

  2008cites this paper
• The effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on oxidative and hypoxic stress in the vascular endothelium

  2008cites this paper
• Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

  2008cites this paper
• Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction

  2008cites this paper
• P450 inhibition profile of mibefradil’s hydrolyzed metabolite, Ro 40-5966 in comparison to

  2008cites this paper
• Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

  2007cites this paper
• The Evolving Role of Drug Metabolism in Drug Discovery and Development

  2007cites this paper
• Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs

  2007cites this paper
• Effect of benidipine on simvastatin metabolism in human liver microsomes.

  2007cites this paper
• Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

  2007cites this paper
• Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.

  2007cites this paper
• Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.

  2007cites this paper
• Nitroso-imidacloprid irreversibly inhibits rabbit aldehyde oxidase.

  2007cites this paper
• Note EŠect of Benidipine on Simvastatin Metabolism in Human Liver Microsomes

  2007cites this paper
• HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system.

  2006cites this paper
• A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

  2006cites this paper
• Metabolites and safety: What are the concerns, and how should we address them?

  2006cites this paper
• The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms Published, JLR Papers in Press, August 2, 2006.

  2006cites this paper
• PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION

  2006cites this paper
• Drug withdrawals and the lessons within.

  2006cites this paper
• ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS

  2006cites this paper
• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006cites this paper
• Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

  2005cites this paper
• AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES

  2005cites this paper
• Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract.

  2005cites this paper
• JPET #93229 1 THE UTILITY OF IN VITRO CYTOCHROME P450 INHIBITION DATA IN THE PREDICTION OF DRUG-DRUG INTERACTIONS

  2005cites this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cites this paper
• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  2005cites this paper
• Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4

  2005cites this paper
• Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance

  2005cites this paper
• Drug Metabolism In Preclinical Development

  2004cites this paper
• Clinical outcomes and management of mechanism-based inhibition of cytochrome P 450 3 A 4

  2004cites this paper
• Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects

  2004cites this paper
• Characterization of the CYP2C8 active site by homology modeling.

  2004cites this paper
• Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin

  2004cites this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cites this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cites this paper
• Pharmacological modulation of ion channels and transporters.

  2004cites this paper
• The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon.

  2004cites this paper
• Characterization of the CYP3A4 active site by homology modeling.

  2004cites this paper
• Pharmakologische Beeinflussung von Ionenkanälen und Transporterproteinen

  2003cites this paper
• Effects of fibrates on metabolism of statins in human hepatocytes.

  2002cites this paper
• Mechanistic studies on metabolic interactions between gemfibrozil and statins.

  2002influential citation
• Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

  2002influential citation
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

  2002cites this paper
• Atorvastatin

  2001cites this paper
• The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.

  2001cites this paper
• Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.

  2001cites this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)

  2001cites this paper